Both CREBBP and EP300 sequence mutations have been reported in solid tumors and, more recently, also in hematological malignancies, whereas rare EP300 mutations have been detected in some ALL cell lines [29, 31]. The gene discussed is EP300; the disease is hematologic disorder.